Prelude Therapeutics Incorporated (PRLD)
| Previous Close | 3.4400 |
| Open | 3.4500 |
| Bid | 2.7800 x 200 |
| Ask | 4.4100 x 200 |
| Day's Range | 3.4500 - 3.8600 |
| 52 Week Range | 1.6600 - 6.8900 |
| Volume | |
| Avg. Volume | 69,400 |
| Market Cap | 201.009M |
| Beta (5Y Monthly) | 1.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0200 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.80 |
Simply Wall St.Several Insiders Invested In Prelude Therapeutics Flagging Positive News
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
GlobeNewswirePrelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targe
- GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitorWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been acc
